{"id":716441,"date":"2022-12-05T07:09:24","date_gmt":"2022-12-05T12:09:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/"},"modified":"2022-12-05T07:09:24","modified_gmt":"2022-12-05T12:09:24","slug":"syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/","title":{"rendered":"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10"},"content":{"rendered":"

<\/p>\n

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10<\/b><\/p>\n

CAMBRIDGE, Mass.–(BUSINESS WIRE<\/a>)–
\nSyros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET.\n<\/p>\n

\nThe event will feature presentations by Syros management, who will review the initial SELECT-AML-1 data and plans for the randomized portion of the Phase 2 trial, as well as Daniel Pollyea, M.D., M.S., Associate Professor of Medicine, Clinical Director of Leukemia Services, University of Colorado School of Medicine, who will provide his perspective on the evolving treatment landscape.\n<\/p>\n

\nParticipants can register for the eventhere<\/a>. <\/i>In addition, a live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com<\/a>. An archived replay of the webcast will be available for approximately 30 days following the presentation.\n<\/p>\n

\nInitial data from the SELECT-AML-1 trial will also be presented on Saturday, December 10, 2022 in a poster session at the 64th<\/sup> American Society of Hematology (ASH) Annual Meeting.\n<\/p>\n

About Syros Pharmaceuticals<\/b><\/p>\n

\nSyros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RAR\u03b1 agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA<\/i> gene overexpression; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com<\/a> and follow us on Twitter (@SyrosPharma<\/a>) and LinkedIn<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20221205005039\/en\/<\/a><\/span><\/p>\n

Syros
\n<\/b>
Karen Hunady
\n
Director of Corporate Communications & Investor Relations
\n
1-857-327-7321
\n
khunady@syros.com
\n<\/a><\/p>\n

Media
\n<\/b>
Brittany Leigh, Ph.D.
\n
LifeSci Communications, LLC
\n
+1-813-767-7801
\n
bleigh@lifescicomms.com
\n<\/a><\/p>\n

Investors
\n<\/b>
Hannah Deresiewicz
\n
Stern Investor Relations, Inc.
\n
212-362-1200
\n
hannah.deresiewicz@sternir.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Clinical Trials Research Pharmaceutical Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET. The event will feature presentations by Syros management, who will review the initial SELECT-AML-1 data and plans for the randomized portion of the … <\/p>\n

Continue reading “Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-716441","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSyros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET. The event will feature presentations by Syros management, who will review the initial SELECT-AML-1 data and plans for the randomized portion of the … Continue reading "Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-05T12:09:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10\",\"datePublished\":\"2022-12-05T12:09:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/\"},\"wordCount\":461,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/\",\"name\":\"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2022-12-05T12:09:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/","og_locale":"en_US","og_type":"article","og_title":"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 - Market Newsdesk","og_description":"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 CAMBRIDGE, Mass.–(BUSINESS WIRE)– Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET. The event will feature presentations by Syros management, who will review the initial SELECT-AML-1 data and plans for the randomized portion of the … Continue reading \"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/","og_site_name":"Market Newsdesk","article_published_time":"2022-12-05T12:09:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10","datePublished":"2022-12-05T12:09:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/"},"wordCount":461,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/","name":"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en","datePublished":"2022-12-05T12:09:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20221205005039r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syros-to-host-virtual-event-to-discuss-initial-select-aml-1-data-and-unmet-need-in-newly-diagnosed-unfit-acute-myeloid-leukemia-on-december-10\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Syros to Host Virtual Event to Discuss Initial SELECT-AML-1 Data and Unmet Need in Newly Diagnosed Unfit Acute Myeloid Leukemia on December 10"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/716441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=716441"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/716441\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=716441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=716441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=716441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}